Active, not recruitingPhase 1NCT00819546

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Studying Inherited acute myeloid leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Richard Stone, MD
Principal Investigator
Richard Stone, MD
Dana-Farber Cancer Institute
Intervention
RAD001(drug)
Enrollment
29 enrolled
Eligibility
18 years · All sexes
Timeline
2009 – 2026

Study locations (3)

Collaborators

Beth Israel Deaconess Medical Center · Massachusetts General Hospital · Brigham and Women's Hospital · Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00819546 on ClinicalTrials.gov

Other trials for Inherited acute myeloid leukemia

Additional recruiting or active studies for the same condition.

See all trials for Inherited acute myeloid leukemia →

← Back to all trials